Precision-Driven Biomarker Validation: A Biotech Perspective (Part I)

The balance between assay precision and sensitivity often tilts towards precision. The latter is paramount in biotech applications because it impacts data turnaround times, cost-efficiency, and experimental repeats.

Biomarker validation is a cornerstone for specimen bioanalysis at all stages of drug development. It ensures the generation of reliable, reproducible, and actionable data for informed decision-making in research and clinical settings¹. Biomarkers can be leveraged in establishing new approach methodologies (NAMs) in lieu of preclinical animal studies before experimental medicines get tested in humans². Depending on the complexity of the drug development process, the molecular nature of the analyte, and the specific platform and format needed for measurements, biomarker assays can be automated for better validation outcomes.

Not only does it improve the consistency, reliability, and reproducibility of results, it leads to higher throughput and standardization as well, both of which streamline the validation process^3,4. For clinical or commercial use assays, automation features help to provide the rigor of documentation and traceability for passing audits against regulatory standards (e.g. GLP, GMP, ISO)⁵.

Moreover, automated systems can often be scaled up or down depending on the volume of samples and assay requirements, which supports a validation scenario that may require testing under multiple conditions or with large patient cohorts. These platforms can be adapted to different assay types, facilitating validation across various systems with uniform workflows. With automation tools, data can be generated more rapidly due to reduced processing time per sample and faster throughput. This speeds up the overall validation timeline to meet internal deadlines and move seamlessly from initial assays to validation stages.

The below table showcases selected examples of technology platforms, for which varying degrees of automation can be introduced to improve biomarker assay validation, from reducing variability to enhancing throughput, sensitivity, data integration and mining.

eGuide: Biomarker Solutions from Discovery to Clinical Trials
Learn how strategic biomarker integration can accelerate research & de-risk pipelines to bring life-saving therapies to patients faster. This guide helps you uncover smarter ways to de-risk studies and accelerate timelines, without compromising scientific rigor.
Read the Guide

DNA/RNA Biomarker Analysis 

Protein Biomarker Analysis

Cellular Biomarker Analysis 

Spatial Biology

Generally, ELISA and qPCR platforms tend to be the most straightforward and widely used for biomarker validation. They provide established protocols and are relatively cost-effective. However, for more complex biomarker profiles involving proteinaceous analytes or metabolites, detection platforms with multiplexing capabilities are preferable. If a biomarker is cellular or requires analysis of cell populations, flow cytometric readouts tend to be the contender for single-cell resolution unless spatial information would also be needed.

Regardless of which methods are chosen, costs associated with biomarker development need to be understand, and a well-designed pilot program must be in place first for establishing robust sample handling protocols, optimizing assay performance, and laying the groundwork for larger studies. While sensitivity—the ability to detect low-abundance biomarkers or minimal concentrations of relevant analytes—is important, the consistency and reproducibility of measurements, or precision, frequently takes precedence in biotech applications for several reasons:

• Turnaround Time: Rapid results accelerate internal decision-making throughout the drug development cycle. In time-sensitive research, a precise assay that delivers consistent results quickly is more valuable than a highly sensitive assay that requires multiple repeats or long processing times.
• Consistency and Reproducibility: Highly precise assays minimize inter-assay variability, ensuring results obtained at different times or by different operators are comparable. This is critical for generating reliable data and drawing meaningful conclusions.
• Cost-Efficiency: Reducing the need for re-runs due to inconsistent results translate to significant savings in time, resources, and reagents. In the competitive biotech landscape, cost-effectiveness is a crucial factor in assay selection.

Biotech companies often need to stress on the ability of an assay to consistently and reproducibly deliver accurate results. This comes with fast-paced scenarios that are common in this space, ensuring that data are generated smoothly, within an allocated time and budget, even if assay sensitivity needs to be deprioritized. Once a robust method is established, further optimization can improve sensitivity without sacrificing reliability. In preclinical stages, validation often adopts a go/no-go approach, where establishing precision and accuracy is a prerequisite, even before sensitivity is considered. This ensures that assays meet regulatory requirements and provide reliable data to support subsequent clinical trials.

Navigating Regulatory Landscapes 

National regulatory bodies like the US Federal Drug Administration (FDA) provide guidelines for biomarker validation to ensure scientific rigor and data reliability. The FDA's evolving perspective on biomarker qualification and validation, as reflected in its guidance documents over the past years, emphasize the importance of:

• Prioritizing Precision and Accuracy: Establishing robust precision and accuracy benchmarks before focusing on optimizing sensitivity. This ensures that the assay is fundamentally sound before pushing the limits of detection.
• Robust Preclinical Validation: Conducting thorough preclinical validation to generate sufficient evidence to support clinical decision-making. This involves demonstrating the assay's performance characteristics in relevant models and matrices.
• Harmonized Sample Processing: Implementing standardized sample processing workflows to minimize variability introduced by pre-analytical factors. This includes careful consideration of collection, handling, storage, and preparation procedures.

In January 2025 the agency released its current guidance on bioanalytical method validation for biomarkers. These point sponsors to apply M10 criteria published in 2022 when submitting biomarker data associated with regulatory approvals, whereas companies can decide on the scope of validation for biomarker assays that support their internal decisions. 

Adhering to all these guidelines enable biotech companies to develop robust biomarker assays that can reliably support downstream clinical research and minimize delays and the need for costly modifications. Compliance with evolving regulatory expectations is essential for successful drug development and approval.

References: 
1.    Han, Y., (2024) Biomarker Analysis in Drug Development: Boosting Precision Medicine - Crown Bioscience. https://blog.crownbio.com/biomarker-analysis-drug-development-precision-medicine
2.    Hartung T, King NMP, Kleinstreuer N, et al. Leveraging biomarkers and translational medicine for preclinical safety - Lessons for advancing the validation of alternatives to animal testing”, ALTEX-ALTERN ANIM EX, 2024, 41:545-566. https://doi.org/10.14573/altex.2410011
3.    Wang J, Patel V, Burns D, et al. Laboratory automation of high-quality and efficient ligand-binding assays for biotherapeutic drug development. Bioanalysis, 2013, 5:1635-1648. https://doi.org/10.4155/bio.13.141
4.    van de Merbel N, Gnoth MJ, Wilson A, et al. Perspective on LC-MS(/MS) for biotherapeutic and biomarker proteins in research and regulated bioanalysis: a consolidation of more than a decade of experience across the European Bioanalysis Forum community (Part 2: “The How”). Bioanalysis, 2024, 17:71-77. https://doi.org/10.1080/17576180.2024.2418251
5.    Zhou M. Regulated bioanalytical laboratories: technical and regulatory aspects from global perspectives. 2011, John Wiley & Sons.